Slingshot members are tracking this event:

Immunomedics (IMMU) to Complete Phase 3 Pivotal Trial Preparation for IMMU-132 in Metastatic Triple-Negative Breast Cancer in 2H 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 18, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Pivotal Trial, Trial Preparation, Immu-132, Metastatic Triple-negative Breast Cancer, 2h 2016